By STEVEN ZECOLA
Recursion Prescription drugs introduced outcomes at present for one its AI-discovered therapies. I used to be happy to see the big, sustained discount in polyps attributable to its therapy for Familial Adenomatous Polyposis. Recursions’ oral treatment will probably be seen by the standard scientific and regulatory group as “promising”.
However, I used to be dissatisfied to not see/hear any reference to the financial savings of the fee to society from this therapy and a obscure reference to working with the FDA in 1H2026. Fairly frankly, the urgency appeared to be missing.
Presently, treating FAP is an costly, lifelong endeavor for the 50,000+ survivors. Early detection methods value $10k+ and late detection $37k+. The fee to treating metastatic colorectal most cancers (for which FAP predisposes) could be extraordinarily excessive, as much as $300,000. Total, the fee to society from FAP simply exceeds $1 billion per 12 months, or greater than $15 billion on a gift worth foundation.
This treatment shouldn’t be topic to any additional regulatory delay. There may be sufficient info now on efficacy and security to have Recursion extra ahead with a broad software of this therapy, whereas persevering with check dosage ranges and stratifying the affected person inhabitants. The choice is extra useless value and struggling.
Steve Zecola offered his internet software and internet hosting enterprise when he was recognized with Parkinson’s illness twenty three years in the past. Since then, he has run a consulting apply, taught in graduate enterprise faculty, and exercised extensively
